Shares of Swiss medical technology company Ypsomed fell 7.2% to 354 Swiss francs on Friday, marking the largest single-day loss in more than six months, after UBS downgraded the stock from "Buy" to "Neutral."
UBS analyst Tanya Hansalik cited declining expectations for Novo Nordisk's obesity treatment CagriSema, for which Ypsomed supplies auto-injector devices. The downgrade came a day after Morgan Stanley also downgraded Novo Nordisk to "Sell," sending the Danish pharmaceutical company's shares lower by more than 4.3%. Novo Nordisk's stock has now fallen more than 20% over the past twelve months.
The double blow to the value chain surrounding weight-loss drugs pressured all connected firms on Friday. Analysts noted that Ypsomed's performance remains heavily tied to Novo Nordisk's commercial trajectory, particularly regarding auto-injector order volumes.
Chart-wise, the correction has weakened Ypsomed's technical posture. Key support levels sit at 351 Swiss francs and 340 Swiss francs. A break below the 340-franc zone could open the path toward 300 francs, roughly the level seen before Ypsomed's May earnings report. On the upside, 393 francs represents the first meaningful resistance, with the new UBS target of 400 francs as the next hurdle; a sustained move above that level would be needed to open the door toward 420 francs.
Fundamentally, Ypsomed recently beat analyst expectations, but further momentum depends on the developments at Novo Nordisk. New setbacks in clinical trials against competitor Eli Lilly have dampened market prospects for Novo Nordisk's adiposity medications. Eli Lilly's tirzepatide again outperformed Novo Nordisk's preparation in recent studies.
Over the coming months, investors will focus on further clinical data for CagriSema and actual auto-injector uptake figures. Lowering expectations ahead of the next earnings reports — Novo Nordisk on Nov. 4 and Ypsomed on Nov. 11 — could create conditions for a positive surprise in either case. Novo Nordisk is also hosting a capital markets day on Sept. 21.
